Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2463${count})

  • Biomarkers, 2007
    Prospective Validation of Risk Markers for the Development of Parkinson’s Disease

    Objective/Rationale:
    The development of disease-course modifying or neuroprotective treatments is still an unmet therapeutical need in Parkinson’s disease. Treatment will likely work best if initiated...

  • Biomarkers, 2007
    A Gene Expression Signature for the Early Detection of Parkinson Disease

    Objective/Rationale:
    The primary goal for the project is to develop a highly accurate and reproducible gene expression signature in blood to discriminate Parkinson disease both from other closely...

  • Biomarkers, 2007
    Validation of CSF Alpha-synuclein as a Biomarker for Parkinson's disease

    Objective/Rationale:
    Accumulation of alpha-synuclein within certain nerve cells represents one of the hallmarks of classical Parkinson disease. Our team recently discovered that alpha-synuclein levels...

  • Biomarkers, 2007
    Multimodal MRI Markers for Parkinson's Disease

    Objective/Rationale:
    The assessment of Parkinson’s disease is currently based on clinical symptoms that make an accurate diagnosis challenging, especially early on, when subtle impairment of movement...

  • Biomarkers, 2007
    Isoforms of Alpha-synuclein as Biomarkers for Diagnosis and Progression of Parkinson's Disease

    Objective/Rationale:
    Alpha-synuclein is involved in the development and progression of Parkinson’s disease unequivocally. Our preliminary data has suggested that there were several alpha-synuclein...

  • LEAPS, 2007
    Therapeutic Development of siRNA Targeting Alpha-Synuclein

    Objective/Rationale:
    Clinical, genetic and experimental evidence supports an association between alpha-synuclein expression and Parkinson’s disease. This toxicity is likely to be attenuated by...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.